Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxart, Inc. (VXRT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain the contents of each document in clear language. As a clinical-stage biotechnology company developing oral recombinant pill vaccines, Vaxart uses its filings to report on clinical progress, collaborations, listing status and material agreements that shape its vaccine platform and financial position.
Through Vaxart’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, investors can review detailed discussions of its oral vaccine programs for coronavirus, norovirus, influenza and HPV, as well as information on research and development spending, government contract revenue and risk factors. Current reports on Form 8‑K highlight specific events, such as the exclusive license and collaboration agreement with Dynavax Technologies Corporation for Vaxart’s oral COVID-19 vaccine candidate, updates on the BARDA-funded Project NextGen Phase 2b trial, lease terminations related to cost reduction efforts, and governance and listing developments.
For trading status, Vaxart’s 8‑K filings and the Form 25 filed by Nasdaq Stock Market LLC document the suspension and removal of the company’s common stock from Nasdaq and its quotation on the OTCQX Best Market under the symbol VXRT. These filings provide the official record of Vaxart’s transition from a national exchange to OTCQX and the conditions that led to delisting.
On this page, users can also monitor any registration statements, prospectus supplements and other capital markets filings that Vaxart uses to raise funds or register securities, as well as any future proxy materials related to corporate actions. Stock Titan’s AI tools summarize long forms such as 10‑K and 10‑Q, highlight key sections on clinical programs, government contracts and collaboration terms, and surface important items from 8‑Ks so that readers can quickly understand how each filing may relate to Vaxart’s oral vaccine development and trading status.
Vaxart, Inc. disclosed that it has entered into a termination agreement with Britannia Pointe Grand Limited Partnership to end its headquarters lease at 170 Harbor Way, South San Francisco. The lease covers approximately 24,606 square feet and will now terminate effective May 15, 2026, instead of the original expiration date of March 31, 2029.
Vaxart will pay rent and reimbursable expenses through the termination date, but will not owe any termination fees or penalties. The change is part of the company’s ongoing efforts to identify cost reduction opportunities. Vaxart intends to relocate its headquarters and labs to one of its other offices in the South San Francisco area.
Vaxart, Inc. insider Michael Finney reported equity transactions in company stock. On December 4, 2025, he acquired 151,351 shares of common stock at a price of $0, reflecting the full vesting of previously granted restricted stock units. On the same date, 54,153 shares were disposed of at $0.37 per share, representing shares withheld by Vaxart to cover income tax obligations tied to the RSU vesting.
After these transactions, Finney beneficially owns 1,787,559 shares of Vaxart common stock directly, plus 100,000 shares held indirectly through the Lo Family Trust. The reported holdings also include 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
Vaxart insider Michael Finney has filed a notice to sell up to 40,000 shares of VXRT common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $14,400.00 listed in the filing. The document also notes that 240,069,844 shares of the issuer’s stock are outstanding.
The 40,000 shares were originally acquired on 02/13/2018 in a private cash transaction from the issuer or an affiliate. In addition, the filing lists recent sales over the past three months, including 51,179 VXRT shares sold on 12/01/2025 for gross proceeds of $18,927.93. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Vaxart.
Vaxart, Inc. director reports open-market stock purchases. A Vaxart (VXRT) director bought 15,000 shares of common stock on 11/17/2025 at a price of $0.41 per share and an additional 5,000 shares at $0.407 per share, both coded as open-market purchases. Following these transactions, the director beneficially owns 124,125 shares of Vaxart common stock in direct ownership form. The report notes that the filing was submitted late due to delays in receiving EDGAR access codes.
Vaxart, Inc. (VXRT) has had its common stock removed from listing and/or registration on the Nasdaq Stock Market LLC. Nasdaq filed Form 25 under Section 12(b) of the Securities Exchange Act of 1934, stating that it has complied with its rules to strike this class of securities from listing and withdraw its registration on the exchange. The filing specifies that the action concerns Vaxart’s common stock, which means the shares will no longer be listed for trading on Nasdaq.
Vaxart, Inc. (VXRT)
Vaxart, Inc. reported third‑quarter results highlighting a sharp rise in government contract revenue and a strengthened liquidity outlook. Revenue reached $72.4 million for the quarter, driven by HHS BARDA contracts tied to the ATI‑RRPV program, while operating expenses were $80.2 million, resulting in an operating loss of $7.8 million and a net loss of $8.1 million (basic and diluted loss per share of $0.04).
Cash, cash equivalents and short‑term investments totaled $28.8 million as of September 30, 2025. The balance sheet reflects $42.7 million in accounts receivable and $43.2 million in unbilled receivables from government contracts, alongside $64.8 million in deferred government revenue. Vaxart recognized $71.8 million of cost‑plus‑fixed‑fee revenue in Q3 under the 2024 ATI‑RRPV Contract.
After quarter‑end, Vaxart entered an exclusive license and collaboration with Dynavax, including a $25.0 million upfront fee and a $5.0 million equity purchase at $0.45 per share, providing approximately $30.0 million in total proceeds. Management reports these actions extend cash runway into the second quarter of 2027. Shares outstanding were 240,069,844 as of November 6, 2025.
Vaxart, Inc. (VXRT) furnished an 8-K to announce it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and stated the information is being furnished, not filed, under the Exchange Act and Securities Act provisions.
Vaxart also noted its common stock trades exclusively on the OTCQX Best Market under the symbol VXRT. No specific financial figures are included in this report; details are contained in the press release referenced as Exhibit 99.1.
Vaxart, Inc. is offering and selling 11,111,111 shares of common stock at $0.45 per share in a privately negotiated transaction with Dynavax Technologies Corporation.
The company estimates net proceeds of approximately $5 million, to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. No underwriters or placement agents are involved. Delivery of shares is expected on or about November 6, 2025. Shares outstanding were 228,957,259 as of September 30, 2025, and are expected to be 240,069,844 immediately after the offering. Vaxart’s stock trades on the OTCQX under VXRT; the last reported price on November 3, 2025 was $0.33 per share.
Vaxart (VXRT) signed an exclusive, worldwide license and collaboration with Dynavax for its investigational oral coronavirus vaccines, including its oral COVID‑19 candidate. Vaxart will complete its ongoing Phase 2b trial and an end‑of‑Phase 2 FDA meeting; after that, Dynavax may elect to assume further development.
Dynavax will pay $25 million upfront and purchase 11,111,111 Vaxart shares at $0.45 per share (about $5 million) under Vaxart’s shelf registration, with closing expected on or about November 6, 2025. If Dynavax elects to take over development, it will pay an additional $50 million.
Vaxart may receive up to $195 million in regulatory milestones, up to $425 million in net sales milestones, and tiered royalties in the low‑to‑mid teens on net sales for licensed indications. Vaxart retains its platform rights for all non‑coronavirus indications. If Dynavax does not elect to continue, the agreement will terminate.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
